Clinical Trial Details


Research Study Summary

Research Study for Chronic Obstructive Pulmonary Disease (COPD)


This is a research study for chronic obstructive pulmonary disease (COPD). Subjects who meet inclusion criteria will be assigned to one of three doses of tiotropium. Two of these doses will be delivered via a novel inhalation device. The third dose will be delivered by the HandiHaler.

This study is for male and female patients age 40 or older who meet spirometry criteria. Patients may not have any other significant respiratory diseases. Oxygen will be allowed if used less than 12 hours per day.

This study is expected to last 2 to 3 ½ years and consist of approximately 10-17 treatment visits. This may change depending on the number of events reported to the pharmaceutical company. At the screening visit, subjects will have a physical examination, EKG and may perform pulmonary function testing at no charge. Subsequent visits will consist of assessment of health and possibly pulmonary function testing. Visit intervals will be from 6 to 12 weeks with interim telephone contacts to assess health and well being.

All study related medication and assessments will be at no charge to the participant. Subjects will be reimbursed for their time and travel.

To Learn more

CW ID: 165992
Date Last Changed: July 23, 2013

Clinical Trial Snapshot

Both Male and Female
40 and up
Overall Status
Facility Type


Jessica Elkins Hochstetler RN, CCRC
Emerald Coast Research Associates
221 East 23rd Street Suite B
Panama City, FL 32405
Phone: 850-785-6550
Fax: 850-785-6804

View Map

Research Center Information:

Emerald Coast Research Associates

DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.